The Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) patient cohort (P4.381)

• DOI: 10.1212/wnl.90.15_supplement.p4.381
• Publication Date: 2023-12-07T11:46:32Z
• Authors: Robert Bermel; Ellen M. Mowry; Lauren Krupp; Stephen Jones; Robert Naismith; Aaron Boster; Megan Hyland; Izlem Izbudak; Yvonne W. Lui; Carrie Hersh; Bjorn Tackenberg; Mar Tintore; Alex Rovira; Xavier Montalban; Hagen H. Kitzler; Tjalf Ziemssen; Eunice Jung; Tatiana Plavina; Carl de Moor; Elizabeth Fisher; Bernd C. Kieseier; Himanshu Pandya; James R. Williams; Richard A. Rudick

Objective: To provide an update on the MS PATHS cohort including prevalence of quality life (QoL) impairment. Background: PATHS, a network 10 healthcare institutions in United States (7) and Europe (3), was designed as Learning Health System (LHS), merging research with patient care by collecting standardized clinical imaging data during routine visits. Enrollment is open to all CIS patients seeking at participating who agree share their for research. Design/Methods: During visits, used iPad-based device, Multiple Sclerosis Performance Test (MSPT), complete history, Quality Life Neurological Disorders (Neuro-QoL) instrument electronic adaptations MSFC. Standardized MRIs were acquired Siemens 3T scanners participants could elect blood samples biorepository. QoL impairment defined Neuro-QoL t-score ≥0.5 standard deviations (SD) worse than reference population mean. Results: As September 8, 2017, 6,362 had opted-in. Data from having completed ≥1 MSPT assessment (n=4998) indicate has average age 47.6 years (SD 12.6), 81.8% white 74.1% female. A relapsing-remitting disease course reported 63.1% cohort; relapses past twelve months 51.2% cohort. The included 27.9% depression, 32.5% stigma, 33.4% fatigue, 44.9% participation social roles. Conclusions: first LHS established MS, should accelerate collaborative MS. Initial results highlight areas unmet need ability participate Further descriptions impairment, its correlates, status longitudinal collection will be presented conference when enrollment expected >10,000 patients. Study Supported by: This study supported Biogen (Cambridge, MA, USA). Disclosure: Dr. Bermel received personal compensation consulting, serving scientific advisory board, speaking, or other activities Biogen, Genzyme, Genentech, Novartis. Mowry editorial capacity UpToDate (royalties). support Teva, SunPharma. Krupp speaker, consultant and/or participant board Idec, Novartis, Teva Neurosciences Multicell; grant National Society, Institutes Department Defense. Celgene Corporation Genentech Lourie Foundation, Slomo Cindy Silvian Foundation Foundation. Jones Monteris. Naismith Acorda, Alkermes, Bayer, EMD Serono, Teva. Boster Novartis genzyme Genetech medtronic. Genetech, Actellion, Roche. Hyland nothing disclose. Izbudak funding form contract her employer, Johns Hopkins University (JHU); primary investigator paid JHU. Lui Hersh Genzyme. Tackenberg Bayer Healthcare, CSL Behring, GRIFOLS, Merck Octapharma, Roche, Sanofi TEVA und UCB Pharma. Frontiers Neurology. Merck. Tintore Schering Pharma, Merck-Serono, Biogen-Idec, Pharmaceuticals, Sanofi-Aventis, Almirall, Rovira Bracco, Sanofi, Stendhal. Montalban Actelion, Celgene, Merck, Oryzon, Pharmaceutical. Kitzler Ziemssen consulting speaking services. Aventis. Jung Employee Biogen. holds stock options Holds stock/stock Plavina DeMoor Fisher Kieseier Pandya Williams Rudick